Iktos is a start-up company based in Paris, France, specializing in developing proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design. With a recent Series A funding of $16,428,000, the company revolutionizes the biotechnology industry. The funding was led by Omnes, M Ventures, and Debiopharm, three prominent venture capital firms.

Iktos' de novo design algorithm is based on deep generative models with reinforcement learning, allowing it to design novel compounds. They are easy to make, optimized to meet a given multi-objective blueprint, and with unprecedented speed, performance, and diversity. This innovative approach to drug design can transform the biotechnology industry. Further, It provides a faster and more efficient way to develop new compounds and bring them to market.

With its cutting-edge technology and deep expertise in drug design, Iktos is well-positioned to become a leader in the biotechnology industry. The company's commitment to innovation and dedication to creating groundbreaking solutions have already caught the attention of industry experts. It poises to make a significant impact in the years to come.

Iktos is an exciting start-up with a promising future in the biotechnology industry. Its unique approach to drug design and innovative technologies have the potential to change the industry's landscape and bring new, life-saving treatments to the market. Visit the link for Iktos's latest funding round https://founderlodge.com/round/Iktos-raises-16428000-Series-A-2023-03-10-Yann-Gaston-Mathe-MTA2MTc